Actively Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
Led by The Second Hospital of Anhui Medical University · Updated on 2026-04-16
282
Participants Needed
6
Research Sites
225 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.
CONDITIONS
Official Title
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) detected on CTA, MRA, or DSA involving specified arterial segments
- Clinical symptoms consistent with MeVO, with NIHSS score 5 - 25 or 3-4 with disabling neurological deficits
- Intra-arterial thrombolysis administered within 24 hours of symptom onset or last known well, or within 24-72 hours meeting specific imaging criteria
- Signed informed consent obtained
You will not qualify if you...
- Pre-stroke modified Rankin Scale score ≥ 2
- Secondary MeVO or severe stenosis caused by endovascular therapy
- Neuroimaging showing intracranial or subarachnoid hemorrhage or other hemorrhagic disorders
- Non-contrast CT showing a clear hypodense lesion corresponding to the vascular territory
- Platelet count <100 × 10⁹/L, bleeding tendency, coagulation factor deficiency, or INR >3.0 due to oral anticoagulants
- Persistent uncontrolled hypertension (systolic >185 mmHg or diastolic >110 mmHg)
- History of intracranial hemorrhage within past 3 months
- Presence of arteriovenous malformations or brain tumors with mass effect
- Gastrointestinal or urinary tract bleeding or major surgery within past 3 months
- Chronic dialysis or severe renal impairment (GFR <30 mL/min or serum creatinine >220 µmol/L)
- Known allergy to thrombolytic agents or iodinated contrast agents
- Pregnant or currently breastfeeding
- Severe systemic diseases with life expectancy less than 3 months
- Deemed unsuitable for participation by the investigator for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Fu Yang People's Hospital
Fuyang, Anhui, China
Actively Recruiting
2
Lin Quan People's Hospital
Fuyang, Anhui, China
Actively Recruiting
3
The Second (Affiliated) Hospital of Anhui Medical University
Hefei, Anhui, China, 230031
Actively Recruiting
4
Shucheng People's Hospital
Lu'an, Anhui, China
Actively Recruiting
5
LiuZhou Worker's Hospital
Liuzhou, Guangxi, China
Actively Recruiting
6
Lishui Central Hospital
Lishui, Zhejiang, China
Actively Recruiting
Research Team
Q
Qi Li, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here